The main technical failures were: chemotherapy product leakage (44%), flow rate anomalies (30%) and injection difficulties (20%). Results: 205 cases of elastomeric pump materialovigilance were identified during the study period. It gathered all the specific reports on elastomeric pumps issued during the period (January 2017-May 2021) by the cytotoxic preparation unit to the materiovigilance cell via a notification form.

Materials and methods: This is a retrospective study conducted at the pharmacy of the National Institute of Oncology in Rabat. Our objective is to study the technical failures of elastomeric pumps in the Cytotoxic Preparation Unit and in the patient’s home, to evaluate the possible impact of these failures on the patient and on the staff and to propose measures to reduce them. However, these pumps are not without risks and can be the cause of incidents due to technical failures. Introduction: Ambulatory chemotherapy is an important and major advance in clinical oncology practice since it allows the administration of chemotherapy in the comfort of the patient’s home without the assistance of a health professional by means of an elastomeric pump.